ABSTRACT
INTRODUCTION: During the surge of the SARS-CoV-2 pandemic, studies revealed high complication and morbidity rates following surgical procedures in COVID-19 positive patients. Anesthetic and surgical societies swiftly developed strategies to mitigate these risks, including a recommended postponement of elective surgeries for a minimum of 7 weeks post-COVID infection. Nowadays, with a predominantly vaccinated population, it has become crucial to discern the influencing factors on post-COVID morbidity and mortality and a reevaluation of the existing recommendations pertaining to elective surgery. METHODS: A single-center case-control study was conducted, including patients who underwent surgery between November 2021 and March 2022 and met the inclusion criteria. Eighty COVID-19 positive patients were matched 1:1 with 80 controls, each undergoing an identical intervention within a 2-week time frame. The primary outcome was 30-day postoperative mortality and secondary outcome postoperative complications (respiratory and thromboembolic). RESULTS: At the time of surgery, 88.8% of patients in the case group and 92.5% in the control group had received at least one vaccine dose. Mortality and morbidity did not show a significant difference when comparing the case and control groups (7.5% vs 6.2%, p = 0.755; 11.3% vs 8.9%, p = 0.541 respectively). In the COVID-positive group, mortality was significantly associated with age over 70 years, ASA score over III, RCRI over 1, emergency procedures, and absence of thromboembolic prophylaxis. CONCLUSIONS: In contrast to previously reported findings, we did not observe an increased morbi-mortality in patients with perioperative COVID-19 infection. It may not be necessary to delay elective interventions, except in cases with a high-risk.
Subject(s)
COVID-19 Vaccines , COVID-19 , Elective Surgical Procedures , Postoperative Complications , Humans , COVID-19/prevention & control , COVID-19/epidemiology , Case-Control Studies , Male , Female , Middle Aged , Postoperative Complications/prevention & control , Postoperative Complications/epidemiology , Aged , COVID-19 Vaccines/administration & dosage , Vaccination , Adult , Aged, 80 and overABSTRACT
No disponible
Subject(s)
Aged , Male , Humans , Fibrosarcoma/etiology , Hand/radiation effects , Radiodermatitis/complications , Skin Neoplasms/etiology , Fibrosarcoma/diagnosis , Fibrosarcoma/surgery , Clinical Evolution , Radiation Exposure , Skin Neoplasms/diagnosis , Skin Neoplasms/surgeryABSTRACT
Los autores aportan un caso de recidiva duodenal por hipernefroma que cursó con clínica digestiva alta en forma de úlcera gigante duodenal hemorrágica, cuya biopsia endoscópica informó de tejido neoplásico de origen renal. Como tratamiento se pudo realizar una duodenopancreatectomía cefálica en cuya pieza de resección se objetivó una afectación duodenopancreática por tumor de células claras compatible con hipernefroma (AU)
